Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Undisclosed
Sponsor : Synaptogenix
Deal Size : $4.0 million
Deal Type : Partnership
Details : Under the partnership, Synaptogenix obtains a preemptive right to fund the further research and commercialization of certain intellectual property, technology, and for cannabinoid- and psilocybin mushroom-based therapeutics for multiple indications.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 11, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Undisclosed
Sponsor : Synaptogenix
Deal Size : $4.0 million
Deal Type : Partnership
Reset All
